Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04221945 · MORE INFO

Limitations, agreements, and source contact

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) · Source last updated 2026-02-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialsDisclosure@merck.com
organization
Merck Sharp & Dohme LLC
phone
1-800-672-6372
title
Clinical Trials Disclosure
Complete source fields
certain Agreement
other Details
If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialsDisclosure@merck.com
organization
Merck Sharp & Dohme LLC
phone
1-800-672-6372
title
Clinical Trials Disclosure

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice